
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
In this clip, Brooke Griffin, PharmD, from Midwestern University, discusses the pharmacist's role in assessing patient eligibility for hormonal contraception.
At the American Pharmacists Association's Annual Meeting (






